Updated: 23rd June 2026
Reviewed by: David Small, BSc (Hons), MSc, MTOPRA (Founder and CEO)
In Vitro Diagnostic Regulations (IVDR) – EU 2017/746
Regulation (EU) 2017/746, commonly known as the In Vitro Diagnostic Medical Device Regulation (IVDR), is the European Union legislation that establishes the legal requirements for placing in vitro diagnostic (IVD) medical devices on the EU market. It replaced the In Vitro Diagnostic Medical Devices Directive (98/79/EC), creating a modern, harmonised regulatory framework that applies directly across all EU Member States.
The Regulation sets out the responsibilities of manufacturers, authorised representatives, importers, distributors, Notified Bodies and Competent Authorities throughout the lifecycle of an IVD medical device. Its primary objective is to ensure that diagnostic devices placed on the European market are safe, perform as intended and continue to meet regulatory requirements after they have been placed on the market.
Unlike the previous Directive, Regulation (EU) 2017/746 introduces a significantly greater level of regulatory oversight. It strengthens requirements for clinical and scientific evidence, technical documentation, quality management systems, post-market surveillance and traceability, while expanding the role of Notified Bodies in conformity assessment for many higher-risk devices.
Today, Regulation (EU) 2017/746 forms the legal foundation for all IVD manufacturers wishing to obtain or maintain CE marking within the European Union. Understanding its structure and requirements is therefore essential for achieving and maintaining market access.
Looking for a Complete IVDR Guide?
This article provides an overview of Regulation (EU) 2017/746. For a comprehensive guide covering IVDR classification, manufacturer obligations, performance evaluation, technical documentation, CE marking, UDI, EUDAMED and post-market surveillance requirements, explore our Complete EU IVDR Guide.
Why Was Regulation (EU) 2017/746 Introduced?
The previous regulatory framework, Directive 98/79/EC (IVDD), was adopted in 1998 when diagnostic technologies were considerably less complex than they are today. Since then, advances in molecular diagnostics, companion diagnostics, genetic testing, artificial intelligence and software-based diagnostic tools have transformed the role of in vitro diagnostics within modern healthcare.
To reflect these developments, the European Commission introduced Regulation (EU) 2017/746 to modernise the legislative framework and strengthen confidence in the safety and performance of IVD medical devices.
The Regulation was designed to:
- Improve patient safety through stronger regulatory oversight.
- Introduce a risk-based classification system for IVDs.
- Strengthen requirements for scientific validity, analytical performance and clinical performance.
- Increase transparency and traceability through Unique Device Identification (UDI).
- Enhance post-market surveillance and vigilance requirements.
- Expand independent conformity assessment by Notified Bodies for higher-risk devices.
- Harmonise regulatory requirements across all European Union Member States.
Rather than focusing solely on obtaining CE marking, Regulation (EU) 2017/746 places greater emphasis on maintaining compliance throughout the entire product lifecycle. Manufacturers are therefore expected to continuously monitor device performance, evaluate real-world data and update their technical documentation whenever new information becomes available.
The Scope of Regulation (EU) 2017/746
Regulation (EU) 2017/746 applies to in vitro diagnostic medical devices (IVDs) intended for use within the European Union. An IVD is any medical device used to examine specimens taken from the human body—such as blood, urine, tissue or saliva—to provide information about a person’s physiological or pathological state, congenital conditions, disease susceptibility, treatment response or compatibility with potential recipients.
The Regulation applies throughout the entire lifecycle of an IVD, from initial design and development through to manufacture, conformity assessment, CE marking, post-market surveillance and eventual withdrawal from the market. It also establishes legal obligations for all economic operators involved in placing IVDs on the European market, including manufacturers, authorised representatives, importers and distributors.
Examples of products that fall within the scope of Regulation (EU) 2017/746 include:
- Clinical chemistry reagents
- Haematology and microbiology test kits
- Molecular and PCR diagnostic tests
- Companion diagnostics
- Genetic testing devices
- Self-testing devices
- Near-patient testing devices
- Laboratory instruments specifically intended for IVD use
- Calibrators and control materials
- Specimen receptacles
- Software intended to provide diagnostic information from in vitro examination results
The Regulation also applies to accessories specifically intended to enable an IVD medical device to be used safely and as intended. These accessories are regulated in their own right and must meet the applicable requirements of the IVDR.
While Regulation (EU) 2017/746 covers a broad range of diagnostic technologies, certain products are excluded from its scope. For example, products intended solely for general laboratory use, research use only (RUO) products that are not intended for diagnostic purposes, and devices without a defined medical purpose may instead fall under other legislative frameworks or may not be regulated as IVD medical devices at all.
Determining whether a product falls within the scope of the IVDR depends primarily on its intended purpose, as defined by the manufacturer. The intended purpose influences how the product is classified, the conformity assessment route that must be followed and the evidence required to demonstrate compliance.
Need help determining whether your product is an IVD? Our experienced regulatory consultants can assess your product’s intended purpose and advise whether Regulation (EU) 2017/746 applies, helping you select the appropriate regulatory pathway from the outset.
The Structure of Regulation (EU) 2017/746
Unlike a guidance document, Regulation (EU) 2017/746 is a legally binding piece of European legislation comprising 10 Chapters and 15 Annexes. Together, these define the legal requirements that manufacturers and other economic operators must meet before an in vitro diagnostic medical device can be placed on the European market.
The Chapters establish the legal obligations for manufacturers, authorised representatives, importers, distributors, Notified Bodies and Competent Authorities, while the Annexes provide the detailed technical requirements for demonstrating conformity.
Understanding the overall structure of the Regulation makes it significantly easier to identify where specific requirements are located and which provisions apply to your organisation.
| Part of the Regulation | Purpose |
|---|---|
| Chapter I | Scope, definitions and general provisions |
| Chapter II | Making devices available on the market and obligations of economic operators |
| Chapter III | Identification, traceability, registration and EUDAMED |
| Chapter IV | Notified Bodies |
| Chapter V | Classification and conformity assessment |
| Chapter VI | Clinical evidence, performance evaluation and performance studies |
| Chapter VII | Post-market surveillance, vigilance and market surveillance |
| Chapter VIII | Cooperation between Member States |
| Chapter IX | Coordination Group |
| Chapter X | Final provisions and transitional arrangements |
The Annexes provide the technical detail needed to demonstrate compliance, covering areas such as General Safety and Performance Requirements (GSPRs), technical documentation, post-market surveillance documentation, classification rules, conformity assessment procedures and performance evaluation.
Rather than attempting to understand the entire Regulation at once, manufacturers often focus on the Chapters and Annexes most relevant to their products and regulatory responsibilities. The following sections summarise the most important parts of Regulation (EU) 2017/746 and explain where to find the key legal requirements.
Key Chapters and Annexes of Regulation (EU) 2017/746
Regulation (EU) 2017/746 is divided into Chapters that establish the legal framework for regulating in vitro diagnostic medical devices and Annexes that provide the detailed technical requirements for demonstrating compliance. While every manufacturer should be familiar with the Regulation as a whole, certain Chapters and Annexes are particularly important during the development, certification and ongoing management of IVDs.
Below is an overview of the sections most frequently referenced during IVDR compliance.
Chapter II – Obligations of Economic Operators
Chapter II establishes the legal responsibilities of manufacturers, authorised representatives, importers and distributors. It explains who is responsible for ensuring that IVDs comply with the Regulation before they are placed on the European market and throughout their lifecycle.
For manufacturers, this Chapter introduces obligations relating to quality management systems, technical documentation, conformity assessment, post-market surveillance, vigilance and regulatory compliance. It also includes the requirement for most manufacturers to appoint a Person Responsible for Regulatory Compliance (PRRC).
Understand Your Obligations Under Article 10 of the IVDR
Regulation (EU) 2017/746 places extensive legal responsibilities on IVD manufacturers. Explore our detailed guide to Article 10 of the EU IVDR to understand the requirements for quality management systems, technical documentation, conformity assessment, post-market surveillance, vigilance and regulatory compliance.
Chapter III – Identification, Traceability and Registration
Chapter III introduces measures designed to improve the traceability of IVD medical devices throughout the supply chain. These include the Unique Device Identification (UDI) system, registration of economic operators and devices, and the use of the European Database on Medical Devices (EUDAMED).
Improved traceability helps Competent Authorities monitor devices throughout their lifecycle, supports more effective market surveillance and enables quicker identification of products affected by safety issues or corrective actions.
Chapter IV – Notified Bodies
Chapter IV defines the designation, responsibilities and oversight of Notified Bodies responsible for conducting conformity assessments under the IVDR.
Unlike the previous IVDD, where many devices could be self-certified, Regulation (EU) 2017/746 requires the majority of Class B, Class C and Class D devices to undergo independent assessment by a Notified Body before CE marking can be achieved. This significantly increases regulatory scrutiny for many manufacturers.
Chapter V – Classification and Conformity Assessment
Chapter V explains how IVD medical devices are classified according to their intended purpose and associated level of risk. It also sets out the conformity assessment procedures that manufacturers must follow before placing devices on the European market.
Device classification determines the level of regulatory oversight required and whether a Notified Body must be involved in the conformity assessment process.
Chapter VI – Performance Evaluation and Performance Studies
Chapter VI establishes the requirements for demonstrating that an IVD performs as intended. Manufacturers must generate and maintain appropriate evidence to support the scientific validity, analytical performance and clinical performance of their devices.
The Chapter also defines the requirements for conducting performance studies where additional evidence is required to demonstrate conformity with the Regulation.
Chapter VII – Post-Market Surveillance and Vigilance
Compliance with Regulation (EU) 2017/746 does not end once a device has been CE marked. Chapter VII requires manufacturers to actively monitor the safety and performance of their devices throughout their lifecycle.
This includes collecting post-market data, investigating complaints, reporting serious incidents to Competent Authorities and implementing field safety corrective actions where necessary. These activities help ensure that devices continue to meet the safety and performance requirements established by the Regulation.
Key Annexes Every Manufacturer Should Understand
While the Chapters establish the legal obligations, the Annexes contain the detailed technical requirements manufacturers must meet when demonstrating conformity with Regulation (EU) 2017/746.
The following Annexes are among the most frequently referenced during IVDR compliance.
| Annex | Purpose |
|---|---|
| Annex I | General Safety and Performance Requirements (GSPRs) that every IVD must satisfy. |
| Annex II | Technical Documentation describing the device, design, manufacturing information and supporting evidence. |
| Annex III | Technical Documentation relating to post-market surveillance activities. |
| Annex VIII | Classification Rules used to determine whether an IVD is Class A, B, C or D. |
| Annex IX | Quality Management System and Technical Documentation conformity assessment route. |
| Annex X | Type Examination procedures for certain conformity assessment routes. |
| Annex XI | Product conformity verification procedures. |
| Annex XIII | Performance Evaluation requirements, including scientific validity, analytical performance and clinical performance. |
| Annex XIV | Performance Studies, including planning, conduct and reporting requirements. |
Rather than viewing the Annexes as standalone documents, they should be considered as interconnected components of the overall regulatory framework. For example, the technical documentation required under Annex II must demonstrate conformity with the General Safety and Performance Requirements set out in Annex I, while the evidence supporting those claims is generated through the performance evaluation process described in Annex XIII.
For this reason, manufacturers typically need to work across multiple Chapters and Annexes simultaneously when developing, certifying and maintaining compliant IVD medical devices.
Demonstrating Compliance with Regulation (EU) 2017/746
Complying with Regulation (EU) 2017/746 requires manufacturers to demonstrate that their devices meet the applicable legal and technical requirements before they are placed on the European market. Unlike the previous IVDD, the IVDR adopts a lifecycle approach to compliance, requiring manufacturers to maintain evidence of conformity from initial product development through to post-market surveillance.
The exact conformity assessment pathway depends on the device classification and intended purpose. However, regardless of classification, manufacturers are expected to establish robust processes that ensure the device remains safe, performs as intended and continues to comply throughout its lifecycle.
Although the specific requirements vary depending on the device, most manufacturers will need to address several core elements during the conformity assessment process.
Define the Intended Purpose
Everything within Regulation (EU) 2017/746 begins with the manufacturer’s intended purpose. The intended purpose determines whether the product falls within the scope of the Regulation, influences device classification and forms the basis for performance evaluation, labelling and regulatory claims.
A clearly defined intended purpose helps ensure that the appropriate conformity assessment route is selected from the outset and reduces the likelihood of regulatory challenges later in the certification process.
Classify the Device
Manufacturers must classify their devices using the rules set out in Annex VIII of the Regulation. Devices are classified into Class A, Class B, Class C or Class D according to the level of risk they present to patients and public health.
The assigned classification determines the level of regulatory oversight and whether independent assessment by a Notified Body is required before CE marking can be achieved.
Prepare Technical Documentation
Manufacturers must compile technical documentation that demonstrates conformity with the applicable requirements of the Regulation. This documentation provides evidence supporting the device design, intended purpose, risk management activities, performance evaluation, manufacturing processes and regulatory compliance.
The documentation should be maintained throughout the product lifecycle and updated whenever significant changes occur.
Generate Appropriate Performance Evidence
One of the most significant changes introduced by the IVDR is the increased emphasis on demonstrating device performance through objective evidence.
Depending on the nature of the device, manufacturers may need to establish scientific validity, analytical performance and clinical performance to support the intended purpose and claims made for the device.
The depth of evidence required will vary according to device classification, intended use and associated risk.
Implement an Appropriate Quality Management System
Manufacturers are expected to establish and maintain a quality management system that supports compliance throughout the product lifecycle.
While the Regulation does not prescribe a specific standard, many organisations implement EN ISO 13485 as the recognised framework for meeting quality management requirements and demonstrating systematic control of design, manufacturing and post-market activities.
Why ISO 13485 Supports IVDR Compliance
While Regulation (EU) 2017/746 does not mandate certification to ISO 13485, implementing a robust quality management system is fundamental to demonstrating ongoing compliance. Learn how ISO 13485 helps manufacturers manage design controls, technical documentation, risk management, supplier oversight and post-market activities throughout the IVD lifecycle.
Complete the Appropriate Conformity Assessment
Depending on the device classification, manufacturers may either self-declare conformity or undergo assessment by a designated Notified Body.
The conformity assessment process evaluates whether the device satisfies the applicable requirements of Regulation (EU) 2017/746 and whether sufficient evidence has been generated to support CE marking.
Maintain Compliance After CE Marking
Compliance with Regulation (EU) 2017/746 continues after a device has been placed on the market.
Manufacturers must monitor device performance, collect post-market information, investigate complaints, report serious incidents where required and maintain their technical documentation to reflect new evidence or product changes.
This continuous approach to regulatory compliance is one of the defining principles of the IVDR and helps ensure that devices remain safe and effective throughout their commercial lifecycle.
Navigating the Regulation Successfully
Regulation (EU) 2017/746 introduces a comprehensive legal framework that can appear complex, particularly for manufacturers bringing new devices to market or transitioning from the previous IVDD. However, the Regulation is designed to ensure that every stage of the product lifecycle—from design and development through to post-market surveillance—is supported by appropriate evidence, effective quality management and ongoing regulatory oversight.
Rather than viewing compliance as a single certification exercise, manufacturers should approach the IVDR as a continuous process of maintaining safety, performance and regulatory conformity throughout the lifetime of their devices.
Patient Guard supports manufacturers at every stage of this journey, providing practical regulatory guidance, technical documentation support, quality management consultancy and strategic advice to help organisations achieve and maintain compliance with Regulation (EU) 2017/746.
Common Challenges When Implementing Regulation (EU) 2017/746
Since becoming applicable in May 2022, Regulation (EU) 2017/746 has fundamentally changed the regulatory landscape for in vitro diagnostic medical devices. While the Regulation aims to improve patient safety and confidence in diagnostic testing, many manufacturers have found the transition considerably more demanding than anticipated.
Understanding these challenges early can help organisations plan more effectively and reduce delays during conformity assessment.
Transitioning from the IVDD
One of the biggest challenges has been transitioning legacy devices from the previous In Vitro Diagnostic Medical Devices Directive (98/79/EC) to the IVDR. Devices that could previously be self-certified may now require Notified Body involvement, additional performance evidence and more comprehensive technical documentation.
Manufacturers should review existing products against the IVDR requirements rather than assuming previous compliance automatically satisfies the new Regulation.
Check the Latest IVDR Transitional Deadlines
Manufacturers of legacy IVDs may still benefit from extended transition periods, but only where the applicable conditions are met. Read our guide to the IVDR transitional provisions and 2026 milestones for an overview of the key deadlines, eligibility requirements and actions manufacturers should be taking now.
Increased Notified Body Involvement
Under the IVDR, significantly more devices require independent conformity assessment by a designated Notified Body. This has increased demand for assessment services and placed greater emphasis on thorough preparation before certification activities begin.
Manufacturers should engage with their chosen Notified Body as early as possible and ensure their documentation is complete before submission to minimise unnecessary delays.
Choosing the Right Notified Body?
Most Class B, Class C and Class D IVDs require assessment by a designated Notified Body before CE marking can be achieved. Read our comprehensive guide to Notified Bodies to learn how they assess conformity, when their involvement is required and how to select the right partner for your certification journey.
Demonstrating Sufficient Performance Evidence
The IVDR places much greater emphasis on objective evidence demonstrating that devices achieve their intended purpose.
Many manufacturers have found that evidence considered acceptable under the IVDD is no longer sufficient. Scientific validity, analytical performance and clinical performance should all be appropriately documented and maintained throughout the product lifecycle.
Generating robust evidence is often one of the most time-consuming aspects of achieving compliance.
Maintaining Technical Documentation
Regulation (EU) 2017/746 requires technical documentation to remain current throughout the lifetime of the device.
Rather than being prepared solely for CE marking, documentation should be reviewed and updated whenever significant design changes, manufacturing changes, new performance data or post-market information become available.
Establishing effective document control processes helps ensure technical files remain inspection-ready at all times.
Keeping Pace with Regulatory Guidance
Although Regulation (EU) 2017/746 establishes the legal framework, its practical interpretation continues to evolve through guidance published by the Medical Device Coordination Group (MDCG), European Commission and Competent Authorities.
Manufacturers should monitor new guidance carefully to ensure their regulatory strategies remain aligned with current expectations and best practice.
Why Early Regulatory Planning Matters
Many of the challenges associated with Regulation (EU) 2017/746 can be significantly reduced through effective planning during product development.
Considering regulatory requirements early allows manufacturers to:
- Define an appropriate intended purpose from the outset.
- Select the correct device classification.
- Generate suitable performance evidence during development.
- Build technical documentation progressively rather than retrospectively.
- Identify the appropriate conformity assessment route.
- Reduce delays before CE marking.
- Avoid costly redesigns or additional testing later in the project.
Taking a proactive approach not only improves regulatory efficiency but can also shorten time to market and reduce the risk of unexpected findings during Notified Body assessment.
How Patient Guard Can Help
Successfully navigating Regulation (EU) 2017/746 requires more than understanding the legislation—it requires applying the requirements effectively throughout the product lifecycle. Whether you are developing a new IVD, transitioning a legacy device or expanding into the European market, obtaining the right regulatory support early can help reduce delays, minimise compliance risks and streamline the conformity assessment process.
At Patient Guard, we support manufacturers across every stage of IVDR compliance, from regulatory strategy and device classification through to technical documentation, performance evaluation, quality management systems and post-market activities. Our consultants work closely with organisations of all sizes to provide practical, proportionate advice that aligns with both the legal requirements of Regulation (EU) 2017/746 and current regulatory expectations.
If you need assistance interpreting the IVDR or preparing your device for CE marking, our team is here to help.
Need Practical Support with IVDR Compliance?
Understanding Regulation (EU) 2017/746 is only the first step. Our guide to IVD consultancy and practical IVDR compliance strategies explains how experienced regulatory consultants can help with device classification, technical documentation, performance evaluation, Notified Body submissions and ongoing compliance throughout the product lifecycle.
Frequently Asked Questions About Regulation (EU) 2017/746
Regulation (EU) 2017/746, also known as the In Vitro Diagnostic Medical Device Regulation (IVDR), is the European Union legislation governing the safety, performance and regulatory requirements for in vitro diagnostic medical devices placed on the EU market. It replaced the In Vitro Diagnostic Medical Devices Directive (98/79/EC) and introduced a modern, risk-based regulatory framework.
The Regulation entered into force on 25 May 2017 and became fully applicable on 26 May 2022. Transitional provisions allow certain legacy devices to remain on the market until specified deadlines, provided they continue to meet the applicable conditions.
The IVDD was replaced because advances in diagnostic technologies, including genetic testing, companion diagnostics and software-based diagnostics, required a stronger regulatory framework. Regulation (EU) 2017/746 introduces more robust requirements for clinical evidence, quality management systems, technical documentation and post-market surveillance.
The Regulation applies to all manufacturers placing in vitro diagnostic medical devices on the European Union market. It also establishes legal obligations for authorised representatives, importers, distributors and other economic operators involved in the supply chain.
The Regulation is European legislation; however, manufacturers located anywhere in the world must comply with its requirements if they intend to place IVD medical devices on the EU market. Non-EU manufacturers are generally required to appoint an EU Authorised Representative.
The Regulation applies to a wide range of in vitro diagnostic medical devices, including laboratory diagnostic tests, companion diagnostics, genetic tests, self-testing devices, near-patient tests, specimen receptacles, calibrators, control materials and software intended for diagnostic purposes. required before CE marking.
Yes. Unlike the previous In Vitro Diagnostic Medical Devices Directive, Regulation (EU) 2017/746 is directly applicable in all EU Member States without requiring implementation through national legislation. This helps ensure consistent regulatory requirements across the European Union.
The IVDR introduces a risk-based classification system, stronger performance evaluation requirements, increased Notified Body involvement, enhanced post-market surveillance, Unique Device Identification (UDI), improved traceability and more comprehensive technical documentation compared with the previous Directive.
No. While many Class B, Class C and Class D devices require independent conformity assessment by a Notified Body, most non-sterile Class A devices may still be self-declared by the manufacturer, provided they meet the applicable requirements of the Regulation.
An IVD is a medical device intended by the manufacturer to examine specimens derived from the human body, such as blood, urine or tissue, to provide information relating to physiological or pathological conditions, congenital conditions, disease susceptibility, treatment response or compatibility with potential recipients.
The complete legal text of Regulation (EU) 2017/746 is available on the EUR-Lex website, the European Union's official database of legislation. Manufacturers should always refer to the latest published version together with relevant MDCG guidance documents when interpreting regulatory requirements.
Patient Guard provides practical regulatory support for manufacturers developing or marketing IVD medical devices in Europe. Our services include regulatory strategy, device classification, technical documentation, performance evaluation, quality management systems, post-market surveillance and ongoing IVDR consultancy to help manufacturers achieve and maintain compliance.
Patient Guards Recent Posts
10 Common Technical Documentation Deficiencies Found During EU MDR and IVDR Notified Body Reviews
Preparing technical documentation for EU MDR or IVDR certification is only half the challenge. Successfully passing a Notified Body review depends on demonstrating consistency across your Quality Management System, Clinical Evaluation, Risk Management, Biological Evaluation, Performance Evaluation and Post-Market Surveillance activities. Discover ten of the most common technical documentation deficiencies identified during MDR and IVDR conformity assessments—and learn how to reduce the likelihood of costly review cycles and certification delays.
EU Authorised Representative Services for Medical Device & IVD Manufacturers
Selling medical devices or IVDs in Europe? If your company is based outside the EU, appointing an EU Authorised Representative (EC Rep) is a legal requirement under EU MDR 2017/745 and IVDR 2017/746. Patient Guard provides expert EU Authorised Representative services, EUDAMED support, regulatory guidance, and ongoing compliance management to help manufacturers access and maintain the European market with confidence.
Predetermined Change Control Plans (PCCPs): The Future of Agile Compliance for Medical Device Software
Learn how PCCPs help medical device software manufacturers manage updates, support AI systems, and enable agile compliance under evolving MDR and UKCA frameworks.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
